• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Genetic variants regulating the immune response improve the prediction of COVID-19 severity provided by clinical variables

tetano

Editor, Senior Moderator
Sci Rep


. 2024 Sep 5;14(1):20728.
doi: 10.1038/s41598-024-71476-2. Genetic variants regulating the immune response improve the prediction of COVID-19 severity provided by clinical variables

Pablo Delgado-Wicke[SUP] #[/SUP][SUP] 1 [/SUP], Sara Fernández de Córdoba-Oñate[SUP] #[/SUP][SUP] 2 3 4 [/SUP], Emilia Roy-Vallejo[SUP] 5 [/SUP], Estíbaliz Alegría-Carrasco[SUP] 1 [/SUP], Diego A Rodríguez-Serrano[SUP] 6 [/SUP], Amalia Lamana[SUP] 7 [/SUP], Nuria Montes[SUP] 2 8 9 [/SUP], Ana Nicolao-Gómez[SUP] 1 [/SUP], Rosa Carracedo-Rodríguez[SUP] 1 [/SUP], Ana Marcos-Jiménez[SUP] 10 [/SUP], Paula Díaz-Fernández[SUP] 10 [/SUP], José M Galván-Román[SUP] 5 [/SUP], Laura Rabes-Rodríguez[SUP] 5 [/SUP], Marta Sanz-Alba[SUP] 5 [/SUP], Jesús Álvarez-Rodríguez[SUP] 5 [/SUP], Almudena Villa-Martí[SUP] 5 [/SUP], Carlos Rodríguez-Franco[SUP] 5 [/SUP], Gonzalo Villapalos-García[SUP] 11 12 [/SUP], Pablo Zubiaur[SUP] 11 12 [/SUP], Francisco Abad-Santos[SUP] 11 12 [/SUP], Ignacio de Los Santos[SUP] 5 13 [/SUP], Rosa P Gomariz[SUP] 7 [/SUP], Rosario García-Vicuña[SUP] 2 14 [/SUP], Cecilia Muñoz-Calleja[SUP] 10 14 13 [/SUP], Isidoro González-Álvaro[SUP] #[/SUP][SUP] 15 [/SUP], Elena Fernández-Ruiz[SUP] #[/SUP][SUP] 16 17 [/SUP]; PREDINMUN-COVID Group



Collaborators, Affiliations
Abstract

The characteristics of the host are crucial in the final outcome of COVID-19. Herein, the influence of genetic and clinical variants in COVID-19 severity was investigated in a total of 1350 patients. Twenty-one single nucleotide polymorphisms of genes involved in SARS-CoV-2 sensing as Toll-like-Receptor 7, antiviral immunity as the type I interferon signalling pathway (TYK2, STAT1, STAT4, OAS1, SOCS) and the vasoactive intestinal peptide and its receptors (VIP/VIPR1,2) were studied. To analyse the association between polymorphisms and severity, a model adjusted by age, sex and different comorbidities was generated by ordinal logistic regression. The genotypes rs8108236-AA (OR 0.12 [95% CI 0.02-0.53]; p = 0.007) and rs280519-AG (OR 0.74 [95% CI 0.56-0.99]; p = 0.03) in TYK2, and rs688136-CC (OR 0.7 [95% CI 0.5-0.99]; p = 0.046) in VIP, were associated with lower severity; in contrast, rs3853839-GG in TLR7 (OR 1.44 [95% CI 1.07-1.94]; p = 0.016), rs280500-AG (OR 1.33 [95% CI 0.97-1.82]; p = 0.078) in TYK2 and rs1131454-AA in OAS1 (OR 1.29 [95% CI 0.95-1.75]; p = 0.110) were associated with higher severity. Therefore, these variants could influence the risk of severe COVID-19.


 
Back
Top Bottom